

Drug and Therapeutics Committee – Minutes – Confirmed

Date / Time	Thursday 8 th February 2018 8:15am – 9.30am
Venue	The Committee Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs Susan Greene, Senior Pharmacy Technician (SG)
Quorate: Yes / No	Yes

Attendance	Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SPG) Prof M Lind, Vice Chair, Professor of Oncology Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mr P O'Brien – Deputy Chief Pharmacist Mr R Kapur, Vascular Surgeon Mrs E Lyle, Locality Pharmacist, Medicines Management, Hull NECS (deputy for KMcC) Dr F Umerah, Consultant Anaesthetist
-------------------	---

Apologies	Mr K McCorry, Medicines Management, East Riding Dr O Ogunbambi, Consultant Rheumatologist
------------------	--

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2018.02.01	Apologies	As above.					
2018.02.02	Declarations of Interest	None					
2018.02.03	Minutes of the previous meeting	The minutes were accepted as a true record.					
2018.02.04	Action Tracker	<p>Bisphosphonates as supportive therapy for Breast Cancer Preparation of a HERPC guideline was in progress.</p> <p>Tedizolid Report SG had added the updated D&TC new product request form onto Pattie</p> <p>Tofacitinib for moderate to severe rheumatoid arthritis Clinical pathway had been written, minor adjustments still to be made.</p> <p>Sarilumab for moderate to severe rheumatoid arthritis NICE TA485 OO had arranged a new product request – on agenda today.</p> <p>Terms of reference for D&TC SPG had updated the ToR to state attendance at 9/12 meetings.</p> <p>Drug company advertising on the HEY Pattie Intranet DC had obtained more information and correspondence was on agenda today.</p> <p>Etelcalcetide injection POB had checked funding and clarified it was from the CCGs. AM had written to all applicants</p>	<p>Ongoing.</p> <p>Action complete.</p> <p>Ongoing.</p> <p>Action complete.</p> <p>Action complete.</p> <p>Action complete.</p> <p>Actions complete.</p>	<p>ML/SS to write guideline for HERPC</p> <p>OO to prepare pathway for next D&TC</p>	<p>ML</p> <p>OO</p>	<p>02/18</p> <p>01/18</p>	<p>02/18</p> <p>02/18</p> <p>02/18</p> <p>02/18</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>Pure fructose (for hydrogen breath testing) POB had arranged a source.</p> <p>Trimbow MDI Updated COPD guideline had been drafted. For circulation to D&TC next month, then take to HERPC.</p> <p>Baricitinib (Olumiant) tablets SPG had received the signed request</p> <p>Guidelines for the use of a High Fibre Supplement to prevent Constipation in Peritoneal Dialysis SPG had a discussion with Katherine Durrans about the drafted guidelines. It was found that these were part of a research proposal with the company. They were not for approval at D&TC and no further action was required.</p> <p>Hull And East Yorkshire Hospitals NHS Trust Guidelines on the Prescribing of Tolvaptan AM had written to the author.</p> <p>Implementing specialised services circulars – NHSE, 19/12/17 DC had escalated to OQC for discussion at the 14/02/18 meeting.</p> <p>Freestyle Libre – Dr B Allen, 20/12/18 SPG had fed back to Dr Allen. The Endocrinology department and Pharmacists had agreed that the device is given free to patients at the HEY diabetes clinic. Consumables will be prescribed and dispensed from the HEY Boots outpatient Pharmacy, with recharge to the CCG. The product will be RED on the joint formulary for 1 year, then to be reviewed.</p> <p>Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable NICE TA492 ML to request application from Dr Butt</p>	<p>Action complete.</p> <p>Ongoing.</p> <p>Action complete.</p> <p>Action complete.</p> <p>Action complete.</p> <p>Action complete.</p> <p>Ongoing.</p>	<p>AM to update HERPC COPD guideline</p>	<p>AM</p> <p>ML</p>	<p>03/18</p> <p>03/18</p>	<p>02/18</p> <p>02/18</p> <p>02/18</p> <p>02/18</p> <p>02/18</p> <p>02/18</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer NICE TA 496 ML to request application</p> <p>Eluxadoline (Truberzi ▼): risk of pancreatitis; do not use in patients who have undergone cholecystectomy or in those with biliary disorders AM had included in letter written to applicant</p>	<p>Ongoing.</p> <p>Action complete.</p>	ML to request application	ML	03//18	02/18
2018.02.05	New Product Requests	<p>Brodalumab – Dr R Zaman Approved as an additional option for psoriasis patients where other biological treatments have not worked, are not tolerated, or patients do not receive a satisfactory response. Supplier has 1p per syringe scheme until 3 months after NICE TA publication. POB to check and sign contract. AM to write to all applicants.</p> <p>Carfilzomib – Dr D Allsup Approved in line with NICE TA457 for first relapse of myeloma in patients not previously treated with bortezomib.</p> <p>Nivolumab – Dr J Bailey Approved in line with NICE TA462 for relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.</p> <p>Sarilumab – Dr Y Patel IL-6 receptor inhibitor, approved in line with NICE TA485 for moderate to severe rheumatoid arthritis.</p>	<p>Approved, subject to review when NICE TA published.</p> <p>Approved.</p> <p>Approved.</p> <p>Approved.</p>	<p>Add to formulary POB to check contract AM to write to all applicants</p> <p>Add to formulary</p> <p>Add to formulary</p> <p>Add to formulary</p>	<p>SG POB AM</p> <p>SG</p> <p>SG</p> <p>SG</p>	<p>03/18 03/18 03/18 03/18</p>	
2018.02.06	Guidelines	None.					02/18
2018.02.07	Correspondence received	<p>Fendix Media - Pharma Campaigns – M Chick, 08/01/18. SPG had circulated to the committee for discussion the Fendix media document “Case for pharma campaigns with Fendix Media”, which is proposes that pharma companies would be able to advertise to specific staff groups on the Pattie intranet site. Generally the committee were more open to the suggestion, than</p>	DC to feed back and ask for an example advert for discussion at the next meeting.	DC to feed back to Bonnie Gray, Web Developer for Pattie	DC	03/18	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		when the idea was previously raised, with the suggested controls. It was decided that an example of some adverts should be made available to the committee. It was felt that these would need to come to D&T and be discussed first. A demonstration would be helpful, so a decision could be made.					
2018.02.08	NICE Guidance January 2018	<p>Age-related macular degeneration https://www.nice.org.uk/guidance/ng82</p> <p>Oesophago-gastric cancer: assessment and management in adults https://www.nice.org.uk/guidance/ng83</p> <p>Sore throat (acute): antimicrobial prescribing https://www.nice.org.uk/guidance/ng84</p> <p>Golimumab for treating non-radiographic axial spondyloarthritis https://www.nice.org.uk/guidance/ta497</p> <p>Lenvatinib with everolimus for previously treated advanced renal cell carcinoma https://www.nice.org.uk/guidance/ta498</p> <p>Glecaprevir–pibrentasvir for treating chronic hepatitis C https://www.nice.org.uk/guidance/ta499</p> <p>Ceritinib for untreated ALK-positive non-small-cell lung cancer https://www.nice.org.uk/guidance/ta500</p> <p>Intrabeam radiotherapy system for adjuvant treatment of early breast cancer https://www.nice.org.uk/guidance/ta501</p> <p>Ibrutinib for treating relapsed or refractory mantle cell lymphoma https://www.nice.org.uk/guidance/ta502</p>	<p>Drugs on formulary.</p> <p>Drugs on formulary.</p> <p>Drugs on formulary.</p> <p>On formulary.</p> <p>Lenvatinib not on formulary, everolimus on formulary.</p> <p>Both drugs not on formulary.</p> <p>Not on formulary.</p> <p>Not NICE recommended in this TA.</p> <p>On CDF list.</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>ML to ask for new product request</p> <p>POB to ask Lorraine Cullen for new product request</p> <p>ML to ask for new product request</p> <p>No further action</p> <p>ML to ask for new product request</p>	<p></p> <p>ML</p> <p>POB</p> <p>ML</p> <p>ML</p>	<p></p> <p>03/18</p> <p>03/18</p> <p>03/18</p> <p>03/18</p> <p>03/18</p> <p>03/18</p>	<p>02/18</p> <p>02/18</p> <p>02/18</p> <p>02/18</p> <p></p> <p>02/18</p> <p></p> <p>02/18</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer https://www.nice.org.uk/guidance/ta503	Not NICE recommended in this TA.	No further action			02/18
2018.02.09	MHRA Drug Safety Update - January 2018	Daclizumab (Zinbryta ▼) and risk of severe liver injury: new restrictions to use and strengthened liver monitoring Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs) Drug-name confusion: reminder to be vigilant for potential errors Co-dydramol: prescribe and dispense by strength to minimise risk of medication error Herbal medicines: report suspected adverse reactions via the Yellow Card Scheme	Noted. Noted. Noted. Noted. Non-formulary. Noted.	No further action No further action No further action No further action No further action			02/18 02/18 02/18 02/18 02/18
2018.02.10	Minutes from the Safe Medication Practice Committee	None					02/18
2018.02.11	Minutes from the Hull and East Riding Prescribing Committee	Confirmed minutes from HERPC November 2017 were considered.	Noted.	No further action			02/18
2018.02.12	Regional Medicines Optimisation Committee Minutes	None.					02/18
2018.02.13	Chairs approvals	None.					02/18

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2018.02.14	Issues to escalate to Operational Quality Committee	None.					02/18
2018.02.15	Any Other Business	None.					02/18
	Date and Time of Next Meeting	Date – Thursday 12th April 2018 Time – 8.15am - 9.30am Venue – Committee Room, Alderson House, HRI					